arrow_back Civic Audit
Share share

Stem Cell and Cord Blood Programs Reauthorized and Funded Through 2031

This act extends funding and operations for programs supporting stem cell transplants and cord blood banks. This means individuals needing these therapies will continue to have access, and research and development in this field will proceed, potentially improving the quality of life for many patients.
Key points
The C.W. Bill Young Cell Transplantation Program will receive an additional $33,009,000 annually for fiscal years 2027-2031.
The national cord blood inventory, crucial for patients seeking donors, has been extended until 2031.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_5160
Sponsor: Rep. Smith, Christopher H. [R-NJ-4]
Process start date: 2025-09-04
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stem Cell Therapeutic and Research Reauthorization Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_5160.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-04.

What are the main provisions?

Key points include:

  • The C.W. Bill Young Cell Transplantation Program will receive an additional $33,009,000 annually for fiscal years 2027-2031.
  • The national cord blood inventory, crucial for patients seeking donors, has been extended until 2031.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Christopher H. [R-NJ-4].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health